Comparison of the Efficacy and Tolerability of Short-Course Cefuroxime Axetil and Amoxicillin/Clavulanic Acid in the Treatment of Secondary Bacterial Infections of Acute Bronchitis A Multicentre, Randomised, Double-Blind Clinical Trial.

Autor: Henry, D.C., Ruoff, G.E., Noonan, M., deAbate, C.A., Puopolo, A.D., Bettis, R., Burroughs, S., Cobb, M., Holley Jr, H.P.
Předmět:
Zdroj: Clinical Drug Investigation; 1999, Vol. 18 Issue 5, p335-344, 10p
Abstrakt: Objective and Study Design: This multicentre, randomised, double-blind clinical trial compared the clinical and bacteriological efficacy and safety of cefuroxime axetil and amoxicillin/clavulanic acid in the treatment of secondary bacterial infections of acute bronchitis (SBIAB). Patients and Methods: 312 patients with signs and symptoms of acute bronchitis were enrolled at 16 centres and randomised to receive either 5 days of treatment with cefuroxime axetil 250mg twice daily (n = 156) or 10 days of treatment with amoxicillin/clavulanic acid 875/125mg twice daily (n = 156). Patients were assessed once during treatment (3 to 5 days) and twice post-treatment (1 to 4 days and 11 to 14 days post-treatment). Results: Organisms were isolated from pretreatment sputum specimens of 294 of 312 (94%) patients, common pathogens being Haemophilus parainfluenzae, H. influenzae, Moraxella catarrhalis and Streptococcus pneumoniae (39, 23, 9 and 8% of isolates, respectively). 33% of H. influenzae isolates and 88% of M. catarrhalis isolates produced β-lactamase. A satisfactory clinical outcome was achieved in 86% (114 of 133) and 90% (128 of 142) of the clinically evaluable patients treated with cefuroxime axetil or amoxicillin/clavulanic acid, respectively (p = 0.27), at the 11- to 14-day follow-up visit. A satisfactory bacteriological outcome was obtained in 89% (110 of 123) and 92% (123 of 134) of bacteriologically and clinically evaluable patients treated with cefuroxime axetil or amoxicillin/clavulanic acid, respectively (p = 0.516), at the 11- to 14-day follow-up visit. Amoxicillin/clavulanic acid treatment was associated with a greater incidence of drug-related adverse events (32 vs 12%, p < 0.001), particularly gastrointestinal adverse events (23 vs 4%, p < 0.001), than was cefuroxime axetil treatment. Conclusions: Cefuroxime axetil 250mg twice daily for 5 days has similar efficacy to amoxicillin/clavulanic acid 875/125mg twice daily for 10 days in the treatment of acute bronchitis, and produces fewer drug-related adverse events. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index